Mutational profiling of kinases in glioblastoma
详细信息 查看全文
- 作者：Fonnet E Bleeker (4) (5) (6)
Simona Lamba (4)
Carlo Zanon (4) (7)
Remco J Molenaar (8)
Theo JM Hulsebos (9)
Dirk Troost (10)
Angela A van Tilborg (10) (11)
W Peter Vandertop (12) (5)
Sieger Leenstra (13) (14)
Cornelis JF van Noorden (8)
Alberto Bardelli (15) (4)
4. Department of Oncology ; University of Torino ; SP 142 ; Km 3.95 ; Candiolo ; Torino ; 10060 ; Italy ; Candiolo Cancer Institute 鈥?FPO ; IRCCS ; Candiolo ; Torino ; Italy
5. Neurosurgical Center Amsterdam ; Location Academic Medical Center ; Meibergdreef 9 ; 1105 ; AZ ; Amsterdam ; The Netherlands
6. Department of Clinical Genetics ; Academic Medical Center and University of Amsterdam ; Meibergdreef 9 ; 1105 ; AZ ; Amsterdam ; The Netherlands
7. Neuroblastoma Laboratory ; Pediatric Research Institute ; Fondazione Citt脿 della Speranza ; Corso Stati Uniti 4 ; 35127 ; Padua ; Italy
8. Department of Cell Biology and Histology ; Academic Medical Center ; University of Amsterdam ; Meibergdreef 9 ; 1105 ; AZ ; Amsterdam ; The Netherlands
9. Department of Neurogenetics ; Academic Medical Center ; University of Amsterdam ; Meibergdreef 9 ; 1105 ; AZ ; Amsterdam ; The Netherlands
10. Department of Neuropathology ; Academic Medical Center ; University of Amsterdam ; Meibergdreef 9 ; 1105 ; AZ ; Amsterdam ; The Netherlands
11. Department of Pathology ; UMC St. Radboud ; Geert Grooteplein-Zuid 10 ; 6525 ; GA ; Nijmegen ; The Netherlands
12. Neurosurgical Center Amsterdam ; Location Vrije Universiteit Medical Center ; De Boelelaan 1117 ; 1081 ; HZ ; Amsterdam ; The Netherlands
13. Department of Neurosurgery ; St. Elisabeth Ziekenhuis ; Hilvarenbeekse Weg 60 ; 5022 ; GC ; Tilburg ; The Netherlands
14. Department of Neurosurgery ; Erasmus Medical Center ; 鈥檚-Gravendijkwal 230 ; 3015 ; CE ; Rotterdam ; The Netherlands
15. FIRC Institute of Molecular Oncology ; Via Adamello 16 ; 20139 ; Milan ; Italy - 关键词：Glioblastoma ; Kinase ; Gene ; Molecular ; Mutation ; PI3K ; AKT
- 刊名：BMC Cancer
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：14
- 期：1
- 全文大小：607 KB
- 参考文献：1. Reddy, EP, Reynolds, RK, Santos, E, Barbacid, M (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300: pp. 149-152 CrossRef
2. Bardelli, A, Parsons, DW, Silliman, N, Ptak, J, Szabo, S, Saha, S, Markowitz, S, Willson, JK, Parmigiani, G, Kinzler, KW, Vogelstein, B, Velculescu, VE (2003) Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300: pp. 949 CrossRef
3. Davies, H, Hunter, C, Smith, R, Stephens, P, Greenman, C, Bignell, G, Teague, J, Butler, A, Edkins, S, Stevens, C, Parker, A, O'Meara, S, Avis, T, Barthorpe, S, Brackenbury, L, Buck, G, Clements, J, Cole, J, Dicks, E, Edwards, K, Forbes, S, Gorton, M, Gray, K, Halliday, K, Harrison, R, Hills, K, Hinton, J, Jones, D, Kosmidou, V, Laman, R (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: pp. 7591-7595
4. Greenman, C, Stephens, P, Smith, R, Dalgliesh, GL, Hunter, C, Bignell, G, Davies, H, Teague, J, Butler, A, Stevens, C, Edkins, S, O'Meara, S, Vastrik, I, Schmidt, EE, Avis, T, Barthorpe, S, Bhamra, G, Buck, G, Choudhury, B, Clements, J, Cole, J, Dicks, E, Forbes, S, Gray, K, Halliday, K, Harrison, R, Hills, K, Hinton, J, Jenkinson, A, Jones, D (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: pp. 153-158 CrossRef
5. Hunter, C, Smith, R, Cahill, DP, Stephens, P, Stevens, C, Teague, J, Greenman, C, Edkins, S, Bignell, G, Davies, H, O'Meara, S, Parker, A, Avis, T, Barthorpe, S, Brackenbury, L, Buck, G, Butler, A, Clements, J, Cole, J, Dicks, E, Forbes, S, Gorton, M, Gray, K, Halliday, K, Harrison, R, Hills, K, Hinton, J, Jenkinson, A, Jones, D, Kosmidou, V (2006) A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: pp. 3987-3991 CrossRef
6. Parsons, DW, Wang, TL, Samuels, Y, Bardelli, A, Cummins, JM, DeLong, L, Silliman, N, Ptak, J, Szabo, S, Willson, JK, Markowitz, S, Kinzler, KW, Vogelstein, B, Lengauer, C, Velculescu, VE (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436: pp. 792 CrossRef
7. Samuels, Y, Wang, Z, Bardelli, A, Silliman, N, Ptak, J, Szabo, S, Yan, H, Gazdar, A, Powell, SM, Riggins, GJ, Willson, JK, Markowitz, S, Kinzler, KW, Vogelstein, B, Velculescu, VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: pp. 554 CrossRef
8. Stephens, P, Edkins, S, Davies, H, Greenman, C, Cox, C, Hunter, C, Bignell, G, Teague, J, Smith, R, Stevens, C, O'Meara, S, Parker, A, Tarpey, P, Avis, T, Barthorpe, A, Brackenbury, L, Buck, G, Butler, A, Clements, J, Cole, J, Dicks, E, Edwards, K, Forbes, S, Gorton, M, Gray, K, Halliday, K, Harrison, R, Hills, K, Hinton, J, Jones, D (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: pp. 590-592 CrossRef
9. Mardis, ER, Ding, L, Dooling, DJ, Larson, DE, McLellan, MD, Chen, K, Koboldt, DC, Fulton, RS, Delehaunty, KD, McGrath, SD, Fulton, LA, Locke, DP, Magrini, VJ, Abbott, RM, Vickery, TL, Reed, JS, Robinson, JS, Wylie, T, Smith, SM, Carmichael, L, Eldred, JM, Harris, CC, Walker, J, Peck, JB, Du, F, Dukes, AF, Sanderson, GE, Brummett, AM, Clark, E, McMichael, J (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361: pp. 1058-1066 CrossRef
10. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P, Mankoo, P, Carter, H, Siu, IM, Gallia, GL, Olivi, A, McLendon, R, Rasheed, BA, Keir, S, Nikolskaya, T, Nikolsky, Y, Busam, DA, Tekleab, H, Diaz, LA, Hartigan, J, Smith, DR, Strausberg, RL, Marie, SK, Shinjo, SM, Yan, H, Riggins, GJ, Bigner, DD, Karchin, R, Papadopoulos, N, Parmigiani, G (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: pp. 1807-1812 CrossRef
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: pp. 1061-1068 CrossRef
11. Futreal, PA, Coin, L, Marshall, M, Down, T, Hubbard, T, Wooster, R, Rahman, N, Stratton, MR (2004) A census of human cancer genes. Nat Rev Cancer 4: pp. 177-183 CrossRef
12. Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, Fleming, T, Eiermann, W, Wolter, J, Pegram, M, Baselga, J, Norton, L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: pp. 783-792 CrossRef
13. Verweij, J, Casali, PG, Zalcberg, J, LeCesne, A, Reichardt, P, Blay, JY, Issels, R, van Oosterom, A, Hogendoorn, PC, Van Glabbeke, M, Bertulli, R, Judson, I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: pp. 1127-1134 CrossRef
14. Chapman, PB, Hauschild, A, Robert, C, Haanen, JB, Ascierto, P, Larkin, J, Dummer, R, Garbe, C, Testori, A, Maio, M, Hogg, D, Lorigan, P, Lebbe, C, Jouary, T, Schadendorf, D, Ribas, A, O'Day, SJ, Sosman, JA, Kirkwood, JM, Eggermont, AM, Dreno, B, Nolop, K, Li, J, Nelson, B, Hou, J, Lee, RJ, Flaherty, KT, McArthur, GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: pp. 2507-2516 CrossRef
15. Douillard, JY, Oliner, KS, Siena, S, Tabernero, J, Burkes, R, Barugel, M, Humblet, Y, Bodoky, G, Cunningham, D, Jassem, J, Rivera, F, Koc谩kova, I, Ruff, P, B艂asi艅ska-Morawiec, M, 艩makal, M, Canon, JL, Rother, M, Williams, R, Rong, A, Wiezorek, J, Sidhu, R, Patterson, SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: pp. 1023-1034 CrossRef
16. Miller, VA, Hirsh, V, Cadranel, J, Chen, YM, Park, K, Kim, SW, Zhou, C, Su, WC, Wang, M, Sun, Y, Heo, DS, Crino, L, Tan, EH, Chao, TY, Shahidi, M, Cong, XJ, Lorence, RM, Yang, JC (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13: pp. 528-538 CrossRef
17. Rini, BI, Escudier, B, Tomczak, P, Kaprin, A, Szczylik, C, Hutson, TE, Michaelson, MD, Gorbunova, VA, Gore, ME, Rusakov, IG, Negrier, S, Ou, YC, Castellano, D, Lim, HY, Uemura, H, Tarazi, J, Cella, D, Chen, C, Rosbrook, B, Kim, S, Motzer, RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: pp. 1931-1939 CrossRef
18. Cortes, JE, Kim, DW, Kantarjian, HM, Brummendorf, TH, Dyagil, I, Griskevicius, L, Malhotra, H, Powell, C, Gogat, K, Countouriotis, AM, Gambacorti-Passerini, C (2012) Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 30: pp. 3486-3492 CrossRef
19. Manning, G, Whyte, DB, Martinez, R, Hunter, T, Sudarsanam, S (2002) The protein kinase complement of the human genome. Science 298: pp. 1912-1934 CrossRef
20. Rand, V, Huang, J, Stockwell, T, Ferriera, S, Buzko, O, Levy, S, Busam, D, Li, K, Edwards, JB, Eberhart, C, Murphy, KM, Tsiamouri, A, Beeson, K, Simpson, AJ, Venter, JC, Riggins, GJ, Strausberg, RL (2005) Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci U S A 102: pp. 14344-14349 CrossRef
21. Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC, Ludwin, SK, Allgeier, A, Fisher, B, Belanger, K, Hau, P, Brandes, AA, Gijtenbeek, J, Marosi, C, Vecht, CJ, Mokhtari, K, Wesseling, P, Villa, S, Eisenhauer, E, Gorlia, T, Weller, M, Lacombe, D, Cairncross, JG, Mirimanoff, RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: pp. 459-466 CrossRef
22. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ, Belanger, K, Brandes, AA, Marosi, C, Bogdahn, U, Curschmann, J, Janzer, RC, Ludwin, SK, Gorlia, T, Allgeier, A, Lacombe, D, Cairncross, JG, Eisenhauer, E, Mirimanoff, RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: pp. 987-996 CrossRef
23. Ohgaki, H, Kleihues, P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64: pp. 479-489
24. Hegi, ME, Rajakannu, P, Weller, M (2012) Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 25: pp. 774-779 CrossRef
25. Beroukhim, R, Getz, G, Nghiemphu, L, Barretina, J, Hsueh, T, Linhart, D, Vivanco, I, Lee, JC, Huang, JH, Alexander, S, Du, J, Kau, T, Thomas, RK, Shah, K, Soto, H, Perner, S, Prensner, J, Debiasi, RM, Demichelis, F, Hatton, C, Rubin, MA, Garraway, LA, Nelson, SF, Liau, L, Mischel, PS, Cloughesy, TF, Meyerson, M, Golub, TA, Lander, ES, Mellinghoff, IK (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: pp. 20007-20012 CrossRef
26. Maher, EA, Brennan, C, Wen, PY, Durso, L, Ligon, KL, Richardson, A, Khatry, D, Feng, B, Sinha, R, Louis, DN, Quackenbush, J, Black, PM, Chin, L, DePinho, RA (2006) Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 66: pp. 11502-11513 CrossRef
27. Bleeker, FE, Molenaar, RJ, Leenstra, S (2012) Recent advances in the molecular understanding of glioblastoma. J Neurooncol 108: pp. 11-27 CrossRef
28. Mir, SE, De Witt Hamer, PC, Krawczyk, PM, Balaj, L, Claes, A, Niers, JM, Van Tilborg, AA, Zwinderman, AH, Geerts, D, Kaspers, GJ, Vandertop, WP, Cloos, J, Tannous, BA, Wesseling, P, Aten, JA, Noske, DP, Van Noorden, CJ, W眉rdinger, T (2010) In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18: pp. 244-257 CrossRef
29. McKusick-Nathans Institute of Genetic Medicine JHUSoM: / Online Mendelian Inheritance in Man (OMIM) database. http://www.omim.org/
30. Institute WTS: / Catalogue of Somatic Mutations in Cancer (COSMIC). http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/
31. Bleeker, FE, Lamba, S, Zanon, C, van Tilborg, AA, Leenstra, S, Troost, D, Hulsebos, T, Vandertop, WP, Bardelli, A (2009) Absence of AKT1 mutations in glioblastoma. PLoS One 4: pp. e5638 CrossRef
32. Bleeker, FE, Atai, NA, Lamba, S, Jonker, A, Rijkeboer, D, Bosch, KS, Tigchelaar, W, Troost, D, Vandertop, WP, Bardelli, A, Van Noorden, CJ (2010) The prognostic IDH1( R132) mutation is associated with reduced NADP鈥?鈥夆垝dependent IDH activity in glioblastoma. Acta Neuropathol 119: pp. 487-494 CrossRef
33. Molenaar, RJ, Verbaan, D, Lamba, S, Zanon, C, Jeuken, JWM, Boots-Sprenger, SHE, Wesseling, P, Hulsebos, TJM, Troost, D, van Tilborg, AA, Leenstra, S, Vandertop, WP, Bardelli, A, Van Noorden, CJ, Bleeker, FE (2014) The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 19: pp. 1263-1267 CrossRef
34. De Witt Hamer, PC, Van Tilborg, AA, Eijk, PP, Sminia, P, Troost, D, Van Noorden, CJ, Ylstra, B, Leenstra, S (2008) The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 27: pp. 2091-2096 CrossRef
35. Gerlach, B, Harder, AH, Hulsebos, TJ, Leenstra, S, Slotman, BJ, Vandertop, WP, Hartmann, KA, Sminia, P (2002) Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures. Strahlenther Onkol 178: pp. 491-496 CrossRef
36. Bielas, JH, Loeb, KR, Rubin, BP, True, LD, Loeb, LA (2006) Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A 103: pp. 18238-18242 CrossRef
37. Sottoriva, A, Spiteri, I, Piccirillo, SG, Touloumis, A, Collins, VP, Marioni, JC, Curtis, C, Watts, C, Tavare, S (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110: pp. 4009-4014 CrossRef
38. Loeb, LA (2011) Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer 11: pp. 450-457 CrossRef
39. Thomas, C, Ely, G, James, CD, Jenkins, R, Kastan, M, Jedlicka, A, Burger, P, Wharen, R (2001) Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. Acta Neuropathol 101: pp. 605-615
40. Ohgaki, H, Dessen, P, Jourde, B, Horstmann, S, Nishikawa, T, Di Patre, PL, Burkhard, C, Schuler, D, Probst-Hensch, NM, Maiorka, PC, Baeza, N, Pisani, P, Yonekawa, Y, Yasargil, MG, L眉tolf, UM, Kleihues, P (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: pp. 6892-6899 CrossRef
41. Rich, JN, Hans, C, Jones, B, Iversen, ES, McLendon, RE, Rasheed, BK, Dobra, A, Dressman, HK, Bigner, DD, Nevins, JR, West, M (2005) Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: pp. 4051-4058 CrossRef
42. Gallia, GL, Rand, V, Siu, IM, Eberhart, CG, James, CD, Marie, SK, Oba-Shinjo, SM, Carlotti, CG, Caballero, OL, Simpson, AJ, Brock, MV, Massion, PP, Carson, BS, Riggins, GJ (2006) PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res 4: pp. 709-714 CrossRef
43. Yan, H, Parsons, DW, Jin, G, McLendon, R, Rasheed, BA, Yuan, W, Kos, I, Batinic-Haberle, I, Jones, S, Riggins, GJ, Friedman, H, Friedman, A, Reardon, D, Herndon, J, Kinzler, KW, Velculescu, VE, Vogelstein, B, Bigner, DD (2009) IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 360: pp. 765-773 CrossRef
44. Bleeker, FE, Lamba, S, Leenstra, S, Troost, D, Hulsebos, T, Vandertop, WP, Frattini, M, Molinari, F, Knowles, M, Cerrato, A, Rodolfo, M, Scarpa, A, Felicioni, L, Buttitta, F, Malatesta, S, Marchetti, A, Bardelli, A (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: pp. 7-11 CrossRef
45. Lee, JC, Vivanco, I, Beroukhim, R, Huang, JH, Feng, WL, DeBiasi, RM, Yoshimoto, K, King, JC, Nghiemphu, P, Yuza, Y, Xu, Q, Greulich, H, Thomas, RK, Paez, JG, Peck, TC, Linhart, DJ, Glatt, KA, Getz, G, Onofrio, R, Ziaugra, L, Levine, RL, Gabriel, S, Kawaguchi, T, O'Neill, K, Khan, H, Liau, LM, Nelson, SF, Rao, PN, Mischel, P, Pieper, RO (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3: pp. e485 CrossRef
46. Brennan, CW, Verhaak, RG, McKenna, A, Campos, B, Noushmehr, H, Salama, SR, Zheng, S, Chakravarty, D, Sanborn, JZ, Berman, SH, Beroukhim, R, Bernard, B, Wu, CJ, Genovese, G, Shmulevich, I, Barnholtz-Sloan, J, Zou, L, Vegesna, R, Shukla, SA, Ciriello, G, Yung, WK, Zhang, W, Sougnez, C, Mikkelsen, T, Aldape, K, Bigner, DD, Van Meir, EG, Prados, M, Sloan, A, Black, KL (2013) The somatic genomic landscape of glioblastoma. Cell 155: pp. 462-477 CrossRef
47. Wood, LD, Parsons, DW, Jones, S, Lin, J, Sjoblom, T, Leary, RJ, Shen, D, Boca, SM, Barber, T, Ptak, J, Silliman, N, Szabo, S, Dezso, Z, Ustyanksky, V, Nikolskaya, T, Nikolsky, Y, Karchin, R, Wilson, PA, Kaminker, JS, Zhang, Z, Croshaw, R, Willis, J, Dawson, D, Shipitsin, M, Willson, JK, Sukumar, S, Polyak, K, Park, BH, Pethiyagoda, CL, Pant, PV (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: pp. 1108-1113 CrossRef
48. Lynch, TJ, Bell, DW, Sordella, R, Gurubhagavatula, S, Okimoto, RA, Brannigan, BW, Harris, PL, Haserlat, SM, Supko, JG, Haluska, FG, Louis, DN, Christiani, DC, Settleman, J, Haber, DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: pp. 2129-2139 CrossRef
49. Stephens, P, Hunter, C, Bignell, G, Edkins, S, Davies, H, Teague, J, Stevens, C, O'Meara, S, Smith, R, Parker, A, Barthorpe, A, Blow, M, Brackenbury, L, Butler, A, Clarke, O, Cole, J, Dicks, E, Dike, A, Drozd, A, Edwards, K, Forbes, S, Foster, R, Gray, K, Greenman, C, Halliday, K, Hills, K, Kosmidou, V, Lugg, R, Menzies, A, Perry, J (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: pp. 525-526 CrossRef
50. Day, BW, Stringer, BW, Al-Ejeh, F, Ting, MJ, Wilson, J, Ensbey, KS, Jamieson, PR, Bruce, ZC, Lim, YC, Offenhauser, C, Charmsaz, S, Cooper, LT, Ellacott, JK, Harding, A, Leveque, L, Inglis, P, Allan, S, Walker, DG, Lackmann, M, Osborne, G, Khanna, KK, Reynolds, BA, Lickliter, JD, Boyd, AW (2013) EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23: pp. 238-248 CrossRef
51. Rohle, D, Popovici-Muller, J, Palaskas, N, Turcan, S, Grommes, C, Campos, C, Tsoi, J, Clark, O, Oldrini, B, Komisopoulou, E, Kunii, K, Pedraza, A, Schalm, S, Silverman, L, Miller, A, Wang, F, Yang, H, Chen, Y, Kernytsky, A, Rosenblum, MK, Liu, W, Biller, SA, Su, SM, Brennan, CW, Chan, TA, Graeber, TG, Yen, KE, Mellinghoff, IK (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340: pp. 626-630 CrossRef
52. Jin, G, Reitman, ZJ, Duncan, CG, Spasojevic, I, Gooden, DM, Rasheed, BA, Yang, R, Lopez, GY, He, Y, McLendon, RE, Bigner, DD, Yan, H (2013) Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73: pp. 496-501 CrossRef
53. Luchman, HA, Stechishin, OD, Dang, NH, Blough, MD, Chesnelong, C, Kelly, JJ, Nguyen, SA, Chan, JA, Weljie, AM, Cairncross, JG, Weiss, S (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14: pp. 184-191 CrossRef
54. Luchman, HA, Chesnelong, C, Cairncross, JG, Weiss, S (2013) Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line. Neuro Oncol 15: pp. 979-980 CrossRef
55. Li, A, Walling, J, Kotliarov, Y, Center, A, Steed, ME, Ahn, SJ, Rosenblum, M, Mikkelsen, T, Zenklusen, JC, Fine, HA (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6: pp. 21-30 CrossRef
56. Balakrishnan, A, Bleeker, FE, Lamba, S, Rodolfo, M, Daniotti, M, Scarpa, A, van Tilborg, AA, Leenstra, S, Zanon, C, Bardelli, A (2007) Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 67: pp. 3545-3550 CrossRef
57. Kita, D, Yonekawa, Y, Weller, M, Ohgaki, H (2007) PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113: pp. 295-302 CrossRef
58. Broderick, DK, Di, C, Parrett, TJ, Samuels, YR, Cummins, JM, McLendon, RE, Fults, DW, Velculescu, VE, Bigner, DD, Yan, H (2004) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: pp. 5048-5050 CrossRef
59. Frattini, M, Signoroni, S, Pilotti, S, Bertario, L, Benvenuti, S, Zanon, C, Bardelli, A, Pierotti, MA (2005) Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 65: pp. 11227 CrossRef
60. Saal, LH, Holm, K, Maurer, M, Memeo, L, Su, T, Wang, X, Yu, JS, Malmstrom, PO, Mansukhani, M, Enoksson, J, Hibshoosh, H, Borg, A, Parsons, R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: pp. 2554-2559 CrossRef
61. Cantley, LC (2002) The phosphoinositide 3-kinase pathway. Science 296: pp. 1655-1657 CrossRef
62. Brugge, J, Hung, MC, Mills, GB (2007) A new mutational AKTivation in the PI3K pathway. Cancer Cell 12: pp. 104-107 CrossRef
63. Grzmil, M, Hemmings, BA (2013) Overcoming resistance to rapalogs in gliomas by combinatory therapies. Biochim Biophys Acta 1834: pp. 1371-1380 CrossRef
64. Sami, A, Karsy, M (2013) Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol 34: pp. 1991-2002 CrossRef
65. Wick, W, Puduvalli, VK, Chamberlain, MC, van den Bent, MJ, Carpentier, AF, Cher, LM, Mason, W, Weller, M, Hong, S, Musib, L, Liepa, AM, Thornton, DE, Fine, HA (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28: pp. 1168-1174 CrossRef
66. Brown, PD, Krishnan, S, Sarkaria, JN, Wu, W, Jaeckle, KA, Uhm, JH, Geoffroy, FJ, Arusell, R, Kitange, G, Jenkins, RB, Kugler, JW, Morton, RF, Rowland, KM, Mischel, P, Yong, WH, Scheithauer, BW, Schiff, D, Giannini, C, Buckner, JC (2008) Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: pp. 5603-5609 CrossRef
67. Haas-Kogan, DA, Prados, MD, Tihan, T, Eberhard, DA, Jelluma, N, Arvold, ND, Baumber, R, Lamborn, KR, Kapadia, A, Malec, M, Berger, MS, Stokoe, D (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: pp. 880-887 CrossRef
68. Yung, WK, Vredenburgh, JJ, Cloughesy, TF, Nghiemphu, P, Klencke, B, Gilbert, MR, Reardon, DA, Prados, MD (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12: pp. 1061-1070 CrossRef
69. Mellinghoff, IK, Wang, MY, Vivanco, I, Haas-Kogan, DA, Zhu, S, Dia, EQ, Lu, KV, Yoshimoto, K, Huang, JH, Chute, DJ, Riggs, BL, Horvath, S, Liau, LM, Cavenee, WK, Rao, PN, Beroukhim, R, Peck, TC, Lee, JC, Sellers, WR, Stokoe, D, Prados, M, Cloughesy, TF, Sawyers, CL, Mischel, PS (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: pp. 2012-2024 CrossRef
70. van den Bent, MJ, Brandes, AA, Rampling, R, Kouwenhoven, MC, Kros, JM, Carpentier, AF, Clement, PM, Frenay, M, Campone, M, Baurain, JF, Armand, JP, Taphoorn, MJ, Tosoni, A, Kletzl, H, Klughammer, B, Lacombe, D, Gorlia, T (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncology 27: pp. 1268-1274 CrossRef
71. Reardon, DA, Desjardins, A, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Herndon, JE, Marcello, J, Norfleet, JA, McLendon, RE, Sampson, JH, Friedman, HS (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96: pp. 219-230 CrossRef
72. Ciriello, G, Miller, ML, Aksoy, BA, Senbabaoglu, Y, Schultz, N, Sander, C (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45: pp. 1127-1133 CrossRef
73. Zack, TI, Schumacher, SE, Carter, SL, Cherniack, AD, Saksena, G, Tabak, B, Lawrence, MS, Zhang, CZ, Wala, J, Mermel, CH, Sougnez, C, Gabriel, SB, Hernandez, B, Shen, H, Laird, PW, Getz, G, Meyerson, M, Beroukhim, R (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45: pp. 1134-1140 CrossRef
74. Roth, AD, Tejpar, S, Delorenzi, M, Yan, P, Fiocca, R, Klingbiel, D, Dietrich, D, Biesmans, B, Bodoky, G, Barone, C, Aranda, E, Nordlinger, B, Cisar, L, Labianca, R, Cunningham, D, Van Cutsem, E, Bosman, F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60鈥?0 trial. J Clin Oncol 28: pp. 466-474 CrossRef
75. Prahallad, A, Sun, C, Huang, S, Di Nicolantonio, F, Salazar, R, Zecchin, D, Beijersbergen, RL, Bardelli, A, Bernards, R (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: pp. 100-103 CrossRef
76. De Witt Hamer, PC, Mir, SE, Noske, D, Van Noorden, CJ, Wurdinger, T (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin Cancer Res 17: pp. 4200-4207 CrossRef
77. Gravendeel, LA, Kouwenhoven, MC, Gevaert, O, de Rooi, JJ, Stubbs, AP, Duijm, JE, Daemen, A, Bleeker, FE, Bralten, LB, Kloosterhof, NK, De Moor, B, Eilers, PH, van der Spek, PJ, Kros, JM, Sillevis Smitt, PA, van den Bent, MJ, French, PJ (2009) Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 69: pp. 9065-9072 CrossRef
78. Phillips, HS, Kharbanda, S, Chen, R, Forrest, WF, Soriano, RH, Wu, TD, Misra, A, Nigro, JM, Colman, H, Soroceanu, L, Williams, PM, Modrusan, Z, Feuerstein, BG, Aldape, K (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: pp. 157-173 CrossRef
79. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD, Miller, CR, Ding, L, Golub, T, Mesirov, JP, Alexe, G, Lawrence, M, O'Kelly, M, Tamayo, P, Weir, BA, Gabriel, S, Winckler, W, Gupta, S, Jakkula, L, Feiler, HS, Hodgson, JG, James, CD, Sarkaria, JN, Brennan, C, Kahn, A, Spellman, PT, Wilson, RK, Speed, TP, Gray, JW, Meyerson, M, Getz, G, Perou, CM, Hayes, DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: pp. 98-110 CrossRef
80. Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA, Kinzler, KW (2013) Cancer genome landscapes. Science 339: pp. 1546-1558 CrossRef
81. Molenaar, RJ, Radivoyevitch, T, Maciejewski, JP, van Noorden, CJ, Bleeker, FE (2014) The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta 1846: pp. 326-341
82. Thompson, CB (2009) Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 360: pp. 813-815 CrossRef
83. van Lith, SA, Navis, AC, Verrijp, K, Niclou, SP, Bjerkvig, R, Wesseling, P, Tops, B, Molenaar, R, van Noorden, CJ, Leenders, WP (2014) Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?. Biochim Biophys Acta 1846: pp. 66-74
84. Lawrence, MS, Stojanov, P, Mermel, CH, Robinson, JT, Garraway, LA, Golub, TR, Meyerson, M, Gabriel, SB, Lander, ES, Getz, G (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505: pp. 495-501 CrossRef
85. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/718/prepub - 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
- 出版者：BioMed Central
- ISSN：1471-2407
文摘
Background Glioblastoma is a highly malignant brain tumor for which no cure is available. To identify new therapeutic targets, we performed a mutation analysis of kinase genes in glioblastoma. Methods Database mining and a literature search identified 76 kinases that have been found to be mutated at least twice in multiple cancer types before. Among those we selected 34 kinase genes for mutation analysis. We also included IDH1, IDH2, PTEN, TP53 and NRAS, genes that are known to be mutated at considerable frequencies in glioblastoma. In total, 174 exons of 39 genes in 113 glioblastoma samples from 109 patients and 16 high-grade glioma (HGG) cell lines were sequenced. Results Our mutation analysis led to the identification of 148 non-synonymous somatic mutations, of which 25 have not been reported before in glioblastoma. Somatic mutations were found in TP53, PTEN, IDH1, PIK3CA, EGFR, BRAF, EPHA3, NRAS, TGFBR2, FLT3 and RPS6KC1. Mapping the mutated genes into known signaling pathways revealed that the large majority of them plays a central role in the PI3K-AKT pathway. Conclusions The knowledge that at least 50% of glioblastoma tumors display mutational activation of the PI3K-AKT pathway should offer new opportunities for the rational development of therapeutic approaches for glioblastomas. However, due to the development of resistance mechanisms, kinase inhibition studies targeting the PI3K-AKT pathway for relapsing glioblastoma have mostly failed thus far. Other therapies should be investigated, targeting early events in gliomagenesis that involve both kinases and non-kinases.